KAT6A and ovarian cancer: Moreover, the interaction between APEX1 and KAT6A or PARP1 was enhanced in PARPi‐resistant ovarian cancer cells during olaparib + cisplatin treatment (Figure 6F,G), indicating the formation of a more stable complex containing KAT6A, PARP1, and APEX1.